Connor, Clark & Lunn Investment Management (CC&L)
LPCN icon

Connor, Clark & Lunn Investment Management (CC&L)’s Lipocine LPCN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-929
Closed -$48K – 881
2016
Q2 		$48K Buy
+929
New +$144K ﹤0.01% 833

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LPCN Position: Q3 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Lipocine (LPCN) in Q3 2016, closing a stake of 929 shares — an estimated $48K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LPCN in Q2 2016 and held it in 1 quarter. The position peaked at $48K in Q2 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q3 2016.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Lipocine position as of Q3 2016 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 929 Lipocine shares in Q3 2016, an estimated $48K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Lipocine in Q2 2016 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Lipocine position peaked at $48K in Q2 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q3 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2016, filed 15 Nov 2016.